Paclitaxel is the prototype of a new class of chemotherapeutic agents with an antimitotic effect that is related to its ability to interfere with the microtubule system. It causes peripheral neurological toxicity by means of its activity on the axonal microtubules. To define the clinical and neurophysiological characteristics of paclitaxel neuropathy 23 patients undergoing paclitaxel therapy at a dose of 175 mg/m2 were studied. The patients were divided into two groups, with only one group receiving pretreatment with potentially neurotoxic drugs such as cisplatin and carboplatin. The results showed a high incidence of mild neurotoxicity in both groups. Treatment was discontinued due to severe neurotoxicity in only one patient pretreated with platinum-compounds. The clinical and neurophysiological data make it possible to define paclitaxel neurotoxicity as a distal axonal neuropathy with a summatory effect in patients pretreated with cisplatin; the possible reversibility of paclitaxel neurotoxicity requires further confirmation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF01999566 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A meta-analysis of the utility of cryotherapy for preventing peripheral neuropathy among breast cancer patients receiving paclitaxel and nab-paclitaxel.
Breast Cancer Res Treat
January 2025
Division of Hematology-Oncology, Upstate Cancer Center, Upstate University Hospital, Syracuse, NY, USA.
Background: Cryotherapy with taxane infusion is a noninvasive strategy for preventing peripheral neuropathy (PN), but the efficacy of this approach has not been proven.
Methods: A systematic search was conducted, and 477 records were initially identified. The titles were screened independently by 2 reviewers.
Multimodal Therapeutic Exercises and Their Role in Mitigating Chemotherapy-Induced Peripheral Neuropathy: A Longitudinal Study on Patient Outcomes.
Cureus
November 2024
Department of Oncology, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, IND.
Introduction A common side effect post chemotherapy is chemotherapy-induced peripheral neuropathy (CIPN). The purpose of this study was to investigate the effect of a multimodal exercise program compared to standard physical therapy in treating CIPN symptoms and improving daily living skills. Aim The aim of this study was to evaluate the effect of multimodal therapeutic exercises and their role in mitigating CIPN symptoms on the neuropathy score and instrumental activities of daily living.
View Article and Find Full Text PDFReal world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer.
Cancer Cell Int
December 2024
Department of Breast Surgery, The People's Hospital of Chuxiong Yi Autonomous Prefecture, No. 318 Lucheng South Road, Chuxiong, 675000, Yunnan, China.
Article Synopsis
- The study compared the efficacy and safety of two chemotherapy regimens—eribulin and utidelone combined with capecitabine—in patients with advanced breast cancer previously treated with anthracyclines and paclitaxel.
- It analyzed data from 85 patients over a five-year period, measuring endpoints such as progression-free survival (mPFS) and overall survival (mOS) using statistical methods like Kaplan‒Meier and Cox regression.
- Results showed that the utidelone/capecitabine group had longer mPFS (7.7 months) and mOS (22.0 months) compared to eribulin (5.2 months mPFS and 18.2 months mOS), indicating
Child outcomes after prenatal exposure to platinum and taxane-based chemotherapy: an unplanned interim analysis of the international network on cancer, infertility, and pregnancy study.
EClinicalMedicine
December 2024
Center for Gynecological Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Background: Platina and taxanes are frequently used chemotherapeutic agents to treat cancer, also when diagnosed during pregnancy. This report presents an interim analysis of the largest series of children prenatally exposed to platinum and/or taxane agents and aims to determine their physical health and neurocognitive outcomes.
Methods: As part of a multicentre, prospective cohort study (ClinicalTrials.
The challenge to identify sensitive safety biomarkers of peripheral neurotoxicity in the rat: A collaborative effort across industry and academia (IMI NeuroDeRisk project).
Toxicology
January 2025
Novartis Pharma AG, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Basel, Switzerland.
Peripheral nervous system (PNS) toxicity assessment in non-clinical safety studies is challenging and relies mostly on histopathological assessment. The present work aims to identify blood-based biomarkers that could detect peripheral neuropathy in rats upon exposure to neurotoxic compounds. Three anticancer agents (oxaliplatin, cisplatin, paclitaxel) and a developmental compound (NVS-1) were assessed in male rats (Wistar Han).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!